Detalhe da pesquisa
1.
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features.
Proc Natl Acad Sci U S A
; 121(4): e2308942121, 2024 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38241441
2.
Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.
PLoS Pathog
; 19(6): e1011469, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37384759
3.
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.
N Engl J Med
; 384(11): 1003-1014, 2021 03 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33730454
4.
Broadly Neutralizing Antibodies for HIV Prevention.
Annu Rev Med
; 71: 329-346, 2020 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31986089
5.
Development of flow cytometry-based assays to assess the ability of antibodies to bind to SARS-CoV-2-infected and spike-transfected cells and mediate NK cell degranulation.
Cytometry A
; 101(6): 483-496, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35301794
6.
Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study.
PLoS Med
; 18(12): e1003868, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34871308
7.
Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features.
PLoS Comput Biol
; 15(4): e1006952, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30933973
8.
Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.
J Infect Dis
; 217(8): 1280-1288, 2018 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29325070
9.
Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.
J Infect Dis
; 215(9): 1376-1385, 2017 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28199679
10.
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.
N Engl J Med
; 369(22): 2083-92, 2013 Nov 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-24099601
11.
Testing the waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial.
Clin Trials
; 12(4): 394-402, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25851992
12.
Sources of racial/ethnic differences in awareness of HIV vaccine trials.
Am J Public Health
; 104(8): e112-8, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24922153
13.
A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087).
medRxiv
; 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38260276
14.
Application of the SLAPNAP statistical learning tool to broadly neutralizing antibody HIV prevention research.
iScience
; 26(9): 107595, 2023 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37654470
15.
Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global region.
J Glob Health
; 13: 06020, 2023 Jun 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37352144
16.
Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US.
Vaccine
; 41(42): 6309-6317, 2023 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37679276
17.
Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01.
Nat Commun
; 14(1): 7813, 2023 Nov 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38016958
18.
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials.
Nat Commun
; 14(1): 8299, 2023 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38097552
19.
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition.
EBioMedicine
; 93: 104590, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37300931
20.
Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants.
Hum Vaccin Immunother
; 18(1): 1908030, 2022 12 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-34213402